Stay updated on Autologous TILs in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Autologous TILs in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Autologous TILs in Solid Tumors Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the information related to a prospective, open-label, multi-cohort Phase 2 study evaluating adoptive cell therapy with TIL LN-144/LN-145 in combination with checkpoint inhibitors or as a single agent therapy for patients with solid tumors.
    Difference
    0.1%
    Check dated 2024-06-06T14:48:15.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for participants, including specific health conditions and prior treatments required for inclusion in the study. Previously, this section only indicated that no information was provided.
    Difference
    31%
    Check dated 2024-05-22T21:36:59.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:35:56.000Z thumbnail image

Stay in the know with updates to Autologous TILs in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Autologous TILs in Solid Tumors Clinical Trial page.